Monoclonal antibodies for malaria prevention

MMV, the Gates Foundation and the US National Institutes of Health are hosting a meeting in Nairobi, Kenya on monoclonal antibodies. The meeting will convene experts to further develop an integrated product development plan for the antimalarial antibody L9LS. The antibody is currently in phase II, and the discussions will be about the fastest way to develop the project and make the antibody available to protect children.